Miflonide (Budesonide)

Budesonide binds to glucocorticoid receptors inside airway cells, altering gene expression to suppress the production of inflammatory cytokines and chemokines. This reduces the recruitment of inflammatory cells, diminishes mucus production, and relaxes airway smooth muscle, resulting in decreased airway swelling and improved airflow.

The specific dose of Miflonide is determined by the prescribing clinician based on the patient’s age, disease severity, and response to therapy. Healthcare providers select the appropriate inhalation strength and frequency, and patients should follow the individualized dosing instructions provided on the prescription label.

Safety data for Budesonide inhalation in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their healthcare professional, as small amounts may be excreted in breast milk.

To request Miflonide, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Miflonide delivers Budesonide, which has a high topical potency and low systemic bioavailability compared with some alternatives such as fluticasone. This profile often results in effective local anti‑inflammatory action with a reduced risk of systemic side effects, making it a preferred option for many clinicians managing asthma and COPD.

Miflonide should be stored at room temperature below 25 °C, protected from moisture and direct sunlight. Keep the inhaler in its original packaging until use, and avoid exposing it to extreme temperatures or humidity, which could affect the stability of the Budesonide formulation.

Miflonide is administered by inhalation using the supplied device. Patients should shake the inhaler (if required), exhale fully, place the mouthpiece in the mouth, and inhale slowly and deeply while actuating the dose. A spacer may be used to improve drug deposition and reduce oral side effects.

Serious risks include adrenal suppression, especially with high‑dose or prolonged use, and an increased susceptibility to respiratory infections such as pneumonia. Rarely, patients may develop severe fungal infections, cataracts, or glaucoma. Prompt medical attention is required if symptoms of these conditions appear.

Miflonide is contraindicated in individuals with a known hypersensitivity to Budesonide or any component of the inhaler. Patients with active, untreated fungal, bacterial, or viral infections of the respiratory tract should avoid use until the infection is resolved, and those on systemic glucocorticoids should be closely monitored.